ABSTRACT
El objetivo del presente trabajo es el de presentar un caso de metástasis a vulva de primario de mama derecha carcinoma lobulillar estadio IIB, en paciente de 46 años con tratamiento quirúrgico y adyuvancia con quimioterapia, radioterapia y hormonoterapia, vista y tratada en el servicio de patología mamaria del Instituto de Oncología Dr. Luis Razetti Caracas, Venezuela. Se revisa la literatura. Se describe una lesión metastásica en labio mayor de hemivulva izquierda de 1,5 cm de diámetro en una paciente con carcinoma lobulillar de mama derecha estadio IIB con intervalo libre de enfermedad de 5 meses después de tratamiento quirúrgico y adyuvante completo. Las metástasis a vulva del cáncer de mama son infrecuentes. La vigilancia ginecológica cuidadosa en pacientes con cáncer de mama permite evidenciar sitios infrecuentes de metástasis, para poder ser diagnosticados precozmente y tratados apropiadamente.
The objective of this present work is to report a case of metastases to vulva of primary of right breast lobulillar carcinoma classified as stadium IIB, in 46 years old patient with surgical and adjuvant treatment with complete chemotherapy, radiotherapy and hormonal therapy she was seen and treated in breast pathology service of Oncology Institute Dr. Luis Razetti, Caracas, Venezuela. We review the literature. Describe a metastatic tumor in left lip bigger of the vulva of 1.5 cm primary of the right breast lobular cancer, stadium IIB, with 5 months interval free of illness, after surgical and adjuvant complete treatment. The metastases to vulva of breast cancer are less frequent. The careful gynecological surveillance in patient with breast cancer allows us to evidence an unusual place of metastasis, to be able to be diagnosed precociously and tried appropriately.
Subject(s)
Humans , Adult , Female , Neoplasm Metastasis/diagnosis , Vulvar Neoplasms/pathology , Hormone Replacement Therapy/methods , Biopsy/methods , Carcinoma, Lobular/surgery , Carcinoma, Lobular/drug therapy , Carcinoma, Lobular/radiotherapy , Breast Neoplasms/etiologyABSTRACT
PURPOSE: To analyze the impact of postmastectomy radiotherapy on locoregional control and overall survival in patients with carcinoma breast. MATERIALS AND METHODS: Between 1995 and 2000, 688 patients of carcinoma breast were analyzed. Out of these, 608 received postmastectomy radiotherapy and 80 patients were not given any radiation therapy. At a median follow-up of 67 months, the outcomes studied were locoregional recurrence (LRR), distant metastases, disease-free survival (DFS) and overall survival (OS) using univariate and multivariate analyses. RESULTS: The frequency of LRR with or without distant metastases was 8.5%, and distant metastases was seen in 18.7% of patients. On univariate analyses, factors affecting LRR were age < 40 years (0.019), tumor stage ( P = 0.001 ), grade ( P = 0.027 ), pathological nodal status ( P ), deep resection plane (0.041), ER/PR status ( P = 0.032 ) and postmastectomy radiation therapy (PMRT) ( P ). DFS rate was 69% at 5 years. Factors affecting distant metastases were age < 40 years (0.005), tumor stage ( P ), grade ( P = 0.0007 ), pathological nodal status ( P ), extra capsular extension (ECE) ( P = 0.002 ), hormonal therapy ( P ) and PMRT ( P ). The OS rate was 81% at 5 years. Factors affecting OS were tumor stage ( P ), grade ( P = 0.0001 ), pathological nodal status ( P ), ECE ( P = 0.002 ) ER/PR status ( P = 0.008 ), hormonal therapy ( P = 0.001 ) and PMRT ( P = 0.004 ). On multivariate analysis, factors affecting LRR were age ( P = 0.001 ), tumor stage ( P = 0.021 ), deep resection plane (0.003), ECE ( P = 0.022 ) and PMRT ( P = 0.047 ). Factors affecting distant metastases were menopause ( P = 0.044 ), grade ( P = 0.012 ), ECE ( P = 0.017 ) and PMRT ( P = 0.012 ). Factors affecting OS were menopausal status ( P = 0.017 ), tumor stage ( P = 0.029 ), pathological nodal status ( P = 0.011 ) and PMRT ( P = 0.002 ). CONCLUSION: PMRT improves LRR as well as OS in patients with carcinoma breast. Other factors of prognostic importance were menopausal status, tumor stage and pathological nodal status.